Characteristics and circumstances of synthetic cannabinoid-related death

References

• Griffiths P, Sedefov R, Gallegos AN, et al. How globalization and market innovation challenge how we think about and respond to drug use: ‘Spice’ a case study. Addiction. 2010;105:951–953.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime. World Drug Report 2019. Geneva: United Nations Office on Drugs and Crime; 2019.
   Google Scholar
• Adams AJ, Banister SD, Irizarry L, et al. “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med. 2017;376:235–242.
   PubMed Web of Science ®Google Scholar
• Banister SD, Connor M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: evolution. Handb Exp Pharmacol. 2018;252:191–226.
   PubMedGoogle Scholar
• Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.
   PubMed Web of Science ®Google Scholar
• Meyer MR. New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics. Arch Toxicol. 2016;90:2421–2444.
   PubMed Web of Science ®Google Scholar
• Tracy DK, Wood DM, Baumeister D. Novel psychoactive substances: types, mechanisms of action and effects. BMJ. 2017;356:i6848.
   PubMed Web of Science ®Google Scholar
• Darke S, Lappin J, Farrell M. The clinician’s guide to illicit drugs and health. London: Silverback Publishing; 2019.
   Google Scholar
• Gurney SM, Scott KS, Kacinko SL, et al. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev. 2014;26:53–78.
   PubMedGoogle Scholar
• Logan BK, Mohr ALA, Friscia M, et al. Reports of adverse events associated with use of novel psychoactive substances, 2013–2016: a review. J Anal Toxicol. 2017;41:573–610.
   PubMed Web of Science ®Google Scholar
• Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol. 2016;54:1–13.
   PubMed Web of Science ®Google Scholar
• White CM. The pharmacologic and clinical effects of illicit synthetic cannabinoids. J Clin Pharmacol. 2017;57:297–304.
   PubMed Web of Science ®Google Scholar
• Von Der Haar J, Talebi S, Ghobadi F, et al. Synthetic cannabinoids and their effects on the cardiovascular system. J Emerg Med. 2016;50:258–262.
   PubMed Web of Science ®Google Scholar
• Freeman MJ, Rose DZ, Myers MA, et al. Ischemic stroke after use of the synthetic marijuana “spice”. Neurology. 2013;81:2090–2093.
   PubMed Web of Science ®Google Scholar
• Rose DZ, Guerrero WR, Mokin MV, et al. Hemorrhagic stroke following use of the synthetic marijuana “spice”. Neurology. 2015;85:1177–1179.
   PubMed Web of Science ®Google Scholar
• Sweeney B, Talebi S, Toro D, et al. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med. 2016;34:e121–122.
   PubMed Web of Science ®Google Scholar
• Jinwala FN, Gupta M. Synthetic cannabis and respiratory depression. J Child Adolesc Psychopharmacol. 2012;22:459–462.
   PubMed Web of Science ®Google Scholar
• Mansoor K, Kheetan M, Shahnawaz S, et al. Systematic review of nephrotoxicity of drugs of abuse, 2005-2016. BMC Nephrol. 2017;18:379.
   PubMed Web of Science ®Google Scholar
• Zarifi C, Vyas S. Spice-y kidney failure: a case report and systematic review of acute kidney injury attributable to the use of synthetic cannabis. Perm J. 2017;21:16–160.
   PubMedGoogle Scholar
• Barratt MJ, Seear K, Lancaster K. A critical examination of the definition of ‘psychoactive effect’ in Australian drug legislation. Int J Drug Policy. 2017;40:16–25.
   PubMed Web of Science ®Google Scholar
• Cairns R, Brown JA, Gunja N, et al. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre. Int J Drug Policy. 2017;43:74–82.
   PubMed Web of Science ®Google Scholar
• Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int. 2016;261:e5–10.
   PubMed Web of Science ®Google Scholar
• Angerer V, Jacobi S, Franz F, et al. Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA. Forensic Sci Int. 2017;281:e9–15.
   PubMed Web of Science ®Google Scholar
• Behonick G, Shanks KG, Firchau DJ, et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol. 2014;38:559–562.
   PubMed Web of Science ®Google Scholar
• Gerostamoulos D, Drummer OH, Woodford NW. Deaths linked to synthetic cannabinoids. Forensic Sci Med Pathol. 2015;11:478–478.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Wurita A, Minakata K, et al. Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver. Forensic Toxicol. 2015;33:380–387.
   PubMed Web of Science ®Google Scholar
• Kronstrand R, Roman M, Andersson M, et al. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol. 2013;37:534–541.
   PubMed Web of Science ®Google Scholar
• Labay LM, Caruso JL, Gilson TP, et al. Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int. 2016;260:31–39.
   PubMed Web of Science ®Google Scholar
• Patton AL, Chimalakonda KC, Moran CL, et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci. 2013;58:1676–1680.
   PubMed Web of Science ®Google Scholar
• Saito T, Namera A, Miura N, et al. A fatal case of MAM-2201 poisoning. Forensic Toxicol. 2013;31:333–337.
   Web of Science ®Google Scholar
• Sasaki C, Saito T, Shinozuka T, et al. A case of death caused by abuse of a synthetic cannabinoid N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide. Forensic Toxicol. 2015;33:165–169.
   Web of Science ®Google Scholar
• Shanks KG, Behonick GS. Death after use of the synthetic cannabinoid 5F-AMB. Forensic Sci Int. 2016;262:e21–e24.
   PubMed Web of Science ®Google Scholar
• Shanks KG, Winston D, Heidingsfelder J, et al. Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int. 2015;252:e6–e9.
   PubMed Web of Science ®Google Scholar
• Sharp P, Hudson S, Hikin L, et al. The changing pattern of synthetic cannabinoid use within England, April 2014 to March 2018. Med Sci Law. 2019;59:180.
   PubMed Web of Science ®Google Scholar
• Westin AA, Frost J, Brede WR, et al. Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol. 2015;40:86–87.
   PubMed Web of Science ®Google Scholar
• Kitzman DW, Scholz DG, Hagen PT, et al. Age-related changes in normal human hearts during the first 10 decades of life. Part II (maturity): a quantitative anatomic study of 765 specimens from subjects 20 to 99 years old. Mayo Clin Proc. 1988;63:137–146.
   PubMed Web of Science ®Google Scholar
• Scholz DG, Kitzman DW, Hagen PT, et al. Age-related changes in normal human hearts during the first 10 decades of life. Part I (growth): a quantitative anatomic study of 200 specimens from subjects from birth to 19 years old. Mayo Clin Proc. 1988;63:126–136.
   PubMed Web of Science ®Google Scholar
• IBM Inc. SPSS for Windows, 25.0. Chicago (IL): SPSS Inc.; 2017.
   Google Scholar
• Barratt MJ, Cakic V, Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev. 2013;32:141–146.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2016: trends and developments. Luxembourg: Publications Office of the European Union; 2016.
   Google Scholar
• Home Office. Drug misuse: findings from the 2016/17 Crime Survey for England and Wales Statistical Bulletin 11/17. London: Home Office; 2017.
   Google Scholar
• Palamar JJ, Martins SS, Su MK, et al. Self-reported use of novel psychoactive substances in a US nationally representative survey: prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug Alcohol Depend. 2015;156:112–119.
   PubMed Web of Science ®Google Scholar
• Sutherland R, Peacock A, Whittaker E, et al. New psychoactive substance use among regular psychostimulant users in Australia, 2010–2015. Drug Alcohol Depend. 2016;161:110–118.
   PubMed Web of Science ®Google Scholar
• Darke S, Duflou J, Kaye S. Prevalence and nature of cardiovascular disease in methamphetamine-related death: a national study. Drug Alcohol Depend. 2017;179:174–179.
   PubMed Web of Science ®Google Scholar
• Chapman C, Slade T, Swift W, et al. Evidence for sex convergence in prevalence of cannabis use: a systematic review and meta-regression. J Stud Alcohol Drugs. 2017;78:344–352.
   PubMed Web of Science ®Google Scholar
• Darke S, Duflou J. The toxicology of heroin-related death: estimating survival times. Addiction. 2016;111:1607–1613.
   PubMed Web of Science ®Google Scholar
• Darke S, Kaye S, Duflou J. Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7 year study. Addiction. 2017;112:2191–2201.
   PubMed Web of Science ®Google Scholar
• Sutherland R, Bruno R, Peacock A, et al. Motivations for new psychoactive substance use among regular psychostimulant users in Australia. Int J Drug Policy. 2017;43:23–32.
   PubMed Web of Science ®Google Scholar
• Gerostamoulos D, Elliott S, Walls HC, et al. To measure or not to measure? That is the NPS question. J Anal Toxicol. 2016;40:318–320.
   PubMed Web of Science ®Google Scholar